Clinical trial · Interventional
Letrozole as a Prophylaxis From GTN for Complete Mole Patients
The Prophylactic Role of Aromatase Inhibitor Letrozole in Decreasing the Incidence of Gestational Trophoblastic Neoplasia in Patients With Complete Hydatidiform Mole
NCT05203562CI-TRIAL-00059615unknownPhase 2 / Phase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Prophylactic use of aromatase inhibitor is effective in decreasing the incidence of Gestational Trophoblastic Neoplasia (GTN) in patients with complete hydatidiform mole (CHM)
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gestational Trophoblastic Disease | Gestational Trophoblastic Tumor | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Letrozole tablets | Drug | Letrozole | ALIAS |
| Suction evacuation | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Control group I
- description
- Patients with complete mole treated by evacuation of using suction curettage followed by conservative follow up
- interventionNames
- Procedure: Suction evacuation
- type
- EXPERIMENTAL
- label
- Prophylactic letrozole group II
- description
- Patients with complete mole treated by evacuation of using suction curettage followed by 5mg daily letrozole for 10 days followed by conservative follow up
- interventionNames
- Procedure: Suction evacuation
- Drug: Letrozole tablets
Primary outcomes (7)
- measure
- (β-hCG) level
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 20 Years
- Maximum age
- 40 Years
Show eligibility criteria text
Inclusion Criteria: * Women were diagnosed to have CHM by ultrasound and confirmed by histopathological examination Exclusion Criteria: * Metastatic disease associated with HM at presentation, in which situation chemotherapy, rather than prophylactic treatment, as prescribed, * Late diagnosis of CHM made only by histological examination of curetted material * Uterine evacuation at another hospital and patient seen at the optimum patient care only for follow up
References
Publications (0)
Data not yet available
No reference posted for this study.